Neoplasm |
Cases associated with Omalizumab, n |
Total cases, n |
ROR |
95% CI |
Breast cancer |
232 |
34449 |
4.12 |
3.61 – 4.69 |
Male |
2 |
285 |
5.94 |
1.48 – 23.9 |
Female |
204 |
31917 |
3.41 |
2.97 – 3.92 |
Lung cancer |
85 |
17012 |
3.04 |
2.45 – 3.76 |
Male |
28 |
6858 |
3.46 |
2.38 – 5.01 |
Female |
52 |
7568 |
3.66 |
2.78 – 4.80 |
Prostate cancer |
57 |
13625 |
2.54 |
1.96 – 3.30 |
Colon cancer |
46 |
7595 |
3.68 |
2.76 – 4.92 |
Male |
18 |
3222 |
4.74 |
2.98 – 7.53 |
Female |
25 |
3614 |
3.68 |
2.48 – 5.45 |
Malignant melanoma |
45 |
8258 |
3.31 |
2.47 – 4.44 |
Male |
14 |
3472 |
3.41 |
2.02 – 5.77 |
Female |
26 |
3596 |
3.85 |
2.61 – 5.66 |
Thyroid cancer |
22 |
3841 |
3.48 |
2.29 – 5.30 |
Male |
2 |
771 |
2.19 |
0.55 – 8.77 |
Female |
19 |
2364 |
4.28 |
2.72 – 6.72 |
Leukemia |
21 |
4604 |
2.77 |
1.80 – 4.25 |
Male |
9 |
1928 |
3.95 |
2.05 – 7.61 |
Female |
9 |
2060 |
2.32 |
1.20 – 4.46 |
Neoplasms (total) |
1380 |
515120 |
1.65 |
1.56 – 1.74 |
Male |
415 |
186876 |
1.91 |
1.73 – 2.11 |
Female |
868 |
253586 |
1.84 |
1.72 – 1.97 |